Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
Status:
Completed
Trial end date:
2016-06-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic
(PD) effects of RDEA3170 administered in combination with allopurinol compared with
allopurinol administered alone in adult subjects with gout.